Chronic Myeloid Leukemia Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of potatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
View More
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
View More
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
View More
Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.
View More
Zhenya Tang, MD, PhD, discusses the findings and clinical significance of a study he led on the use of FISH to identify chromosomal abnormalities in patients with CML.
View More
Gary Lyman, MD, comments on the clinical significance and findings of a study he co-conducted on the link between generic imatinib availability and trends in TKI use among patients with CML.
View More
Matt Kalaycio, MD, discusses how treatment for CML has evolved in the past 2 decades, and touches on the IRIS trial, which greatly impacted the treatment landscape for this disease.
View More
Elisabetta Abruzzese, MD, PhD, discusses the history of research pertaining to patients with CML who are pregnant or planning to start a family.
View More
Sonia Amin Thomas, PharmD, BCOP, discusses data regarding the safety and efficacy of bosutinib therapy for patients with chronic-phase CML.
View More
Stay in the know.
OncNet Newsletter